Limits...
Anti-C1q antibodies as a follow-up marker in SLE patients.

Bock M, Heijnen I, Trendelenburg M - PLoS ONE (2015)

Bottom Line: Anti-C1q levels correlated with global disease activity scores.In subgroup analyses, patients without renal involvement did not show a significant correlation between anti-C1q levels and disease activity.In contrast, in patients with renal involvement, anti-C1q levels correlated well with global disease activity.

View Article: PubMed Central - PubMed

Affiliation: Division of Internal Medicine, University Hospital Basel, Basel, Switzerland.

ABSTRACT
In cross-sectional studies autoantibodies against complement C1q (anti-C1q) were found to be highly associated with active lupus nephritis. The aim of this retrospective study was to determine the value of anti-C1q as follow-up marker of disease activity and renal involvement in patients with systemic lupus erythematosus (SLE). Fifty-two patients with SLE and a minimum of three anti-C1q measurements during follow-up were analyzed. Anti-C1q levels correlated with global disease activity scores. In subgroup analyses, patients without renal involvement did not show a significant correlation between anti-C1q levels and disease activity. In contrast, in patients with renal involvement, anti-C1q levels correlated well with global disease activity. In addition, a positive correlation with the urine protein-to-creatinine ratio and anti-dsDNA antibody levels as well as a negative correlation with complement levels was observed. Anti-C1q antibodies were found to strongly correlate with parameters of SLE disease activity during follow-up, in particular with regard to renal involvement.

No MeSH data available.


Related in: MedlinePlus

Correlation between anti-C1q and disease activity indices for (A) patients without renal involvement and (B) patients with renal involvement.Patients without renal involvement did not show a significant correlation between anti-C1q and activity indices (SLEDAI R = 0.05, p = 0.6; ECLAM R = 0.16, p = 0.07) whereas patients with renal involvement in the history showed a significant correlation between anti-C1q levels and activity indices (SLEDAI R = 0.47, p<0.0001; ECLAM R = 0.28, p<0.0001).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4400137&req=5

pone.0123572.g003: Correlation between anti-C1q and disease activity indices for (A) patients without renal involvement and (B) patients with renal involvement.Patients without renal involvement did not show a significant correlation between anti-C1q and activity indices (SLEDAI R = 0.05, p = 0.6; ECLAM R = 0.16, p = 0.07) whereas patients with renal involvement in the history showed a significant correlation between anti-C1q levels and activity indices (SLEDAI R = 0.47, p<0.0001; ECLAM R = 0.28, p<0.0001).

Mentions: Since anti-C1q had been described to particularly well correlate with renal involvement [13–19], we subsequently separated the patients into two groups for further analysis: Group 1 comprising 31 patients with renal involvement (337 measurement points) and group 2 comprising 21 patients without apparent renal involvement ever (123 measurement points). For each group the correlation between anti-C1q levels and the activity indices were investigated separately (Fig 3).


Anti-C1q antibodies as a follow-up marker in SLE patients.

Bock M, Heijnen I, Trendelenburg M - PLoS ONE (2015)

Correlation between anti-C1q and disease activity indices for (A) patients without renal involvement and (B) patients with renal involvement.Patients without renal involvement did not show a significant correlation between anti-C1q and activity indices (SLEDAI R = 0.05, p = 0.6; ECLAM R = 0.16, p = 0.07) whereas patients with renal involvement in the history showed a significant correlation between anti-C1q levels and activity indices (SLEDAI R = 0.47, p<0.0001; ECLAM R = 0.28, p<0.0001).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4400137&req=5

pone.0123572.g003: Correlation between anti-C1q and disease activity indices for (A) patients without renal involvement and (B) patients with renal involvement.Patients without renal involvement did not show a significant correlation between anti-C1q and activity indices (SLEDAI R = 0.05, p = 0.6; ECLAM R = 0.16, p = 0.07) whereas patients with renal involvement in the history showed a significant correlation between anti-C1q levels and activity indices (SLEDAI R = 0.47, p<0.0001; ECLAM R = 0.28, p<0.0001).
Mentions: Since anti-C1q had been described to particularly well correlate with renal involvement [13–19], we subsequently separated the patients into two groups for further analysis: Group 1 comprising 31 patients with renal involvement (337 measurement points) and group 2 comprising 21 patients without apparent renal involvement ever (123 measurement points). For each group the correlation between anti-C1q levels and the activity indices were investigated separately (Fig 3).

Bottom Line: Anti-C1q levels correlated with global disease activity scores.In subgroup analyses, patients without renal involvement did not show a significant correlation between anti-C1q levels and disease activity.In contrast, in patients with renal involvement, anti-C1q levels correlated well with global disease activity.

View Article: PubMed Central - PubMed

Affiliation: Division of Internal Medicine, University Hospital Basel, Basel, Switzerland.

ABSTRACT
In cross-sectional studies autoantibodies against complement C1q (anti-C1q) were found to be highly associated with active lupus nephritis. The aim of this retrospective study was to determine the value of anti-C1q as follow-up marker of disease activity and renal involvement in patients with systemic lupus erythematosus (SLE). Fifty-two patients with SLE and a minimum of three anti-C1q measurements during follow-up were analyzed. Anti-C1q levels correlated with global disease activity scores. In subgroup analyses, patients without renal involvement did not show a significant correlation between anti-C1q levels and disease activity. In contrast, in patients with renal involvement, anti-C1q levels correlated well with global disease activity. In addition, a positive correlation with the urine protein-to-creatinine ratio and anti-dsDNA antibody levels as well as a negative correlation with complement levels was observed. Anti-C1q antibodies were found to strongly correlate with parameters of SLE disease activity during follow-up, in particular with regard to renal involvement.

No MeSH data available.


Related in: MedlinePlus